Evexia Lifecare Reports Strong FY26 Growth Amid Auditor's Red Flags

Evexia Lifecare has reported a significant leap in its FY26 financial results, with profits doubling. However, this strong performance is overshadowed by its auditor flagging substantial risks related to credit loss assessments and the future viability of a key subsidiary.

FY26 Results and Auditor's Concerns

The company announced its audited financial results for the fiscal year ending March 31, 2026. Consolidated revenue climbed 27% to ₹110.28 crore, up from ₹86.59 crore the previous year. Net profit surged to ₹1.62 crore, a nearly five-fold increase from ₹0.41 crore in FY25. Standalone figures also showed robust growth, with revenue more than doubling to ₹106.35 crore and net profit rising to ₹1.52 crore.

Despite this positive financial picture, the auditor issued a qualified opinion. Concerns were raised about the lack of assessment for expected credit losses on loans amounting to ₹735.13 lakh and trade receivables of ₹2,943.89 lakh, suggesting potential unrecorded losses.

Furthermore, the auditor cast significant doubt on the ability of Evexia's subsidiary, Kavit Edible Oil Limited, to continue operating. This subsidiary has suspended manufacturing since March 2019 and reported a negative net worth as of March 31, 2026.

Implications of Audit Warnings

A qualified audit opinion indicates that the auditor has reservations about certain aspects of the financial statements' accuracy or fairness. Issues surrounding a company's ability to continue operating as a "going concern" mean there is considerable uncertainty about its future, which can affect the parent company's overall financial health and investor confidence. These audit flags could lead to increased scrutiny from regulators, lenders, and investors, potentially impacting Evexia's ability to secure future financing or conduct business smoothly.

Company Context

Evexia Lifecare Limited operates in the manufacturing and trading of edible oils and pharmaceuticals. Its subsidiary, Kavit Edible Oil Limited, has been the focus of audit concerns due to its prolonged operational halt since March 2019 and its accumulation of a negative net worth.

Investor Outlook

Investors are likely to be more cautious, awaiting management's clarification regarding the auditor's qualifications. The company may face pressure to improve its credit loss provisioning and address the issues at its subsidiary. Financing may become harder, particularly for Kavit Edible Oil, and potentially for Evexia Lifecare itself if these matters are not resolved.

Key Risks Identified

The main financial risks include the unassessed expected credit losses on ₹735.13 lakh in loans and ₹2,943.89 lakh in trade receivables. The doubts about Kavit Edible Oil's future operations is a significant threat to its viability and could lead to substantial write-downs. Additional concerns noted by the auditor regarding potential misstatements in financial instruments and investments increase uncertainty.

Industry Comparison

In the pharmaceutical sector, Supriya Lifescience Ltd. provides a comparison for Evexia's pharma trading segment. However, Evexia's involvement in edible oils through Kavit Edible Oil means different operational dynamics. The broader edible oil market is shown to be competitive, dominated by major players like Adani Wilmar Ltd., in which Evexia's subsidiary operates on a much smaller scale.

Key Financial Data

Here are the key financial figures for FY2026 compared to FY2025:

• Consolidated Total Revenue: Increased from ₹8,659.04 lakh in FY2025 to ₹11,027.55 lakh in FY2026.
• Consolidated Net Profit: Rose from ₹41.25 lakh in FY2025 to ₹162.13 lakh in FY2026.
• Standalone Total Revenue: Grew from ₹4,388.68 lakh in FY2025 to ₹10,635.03 lakh in FY2026.
• Standalone Net Profit: Increased from ₹72.79 lakh in FY2025 to ₹152.10 lakh in FY2026.

What to Watch Next

Investors will be closely watching management's response and clarifications on the auditor's qualified opinion and going concern remarks. Any plans or restructuring measures for Kavit Edible Oil Limited will be critical. Future disclosures or regulatory filings that address the specific points raised by the auditor, particularly concerning credit loss assessments and valuations, will be important. Additionally, any analyst calls or investor briefings that offer further insight into the company's risk mitigation strategies will be closely monitored.